Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Overview of attention for article published in Cardiovascular Diabetology, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 60 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 4 policy documents that reference this research output.

dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Aug 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Jul 2023

NRL: Farmakologisk glukosesænkende behandling af type 2-diabetes

Cited by Danish Health Authority on 29 Sep 2020

The Danish Health Authority advises municipalities and regions and comes up with recommendations, guidelines and action plans, to promote public health and create a good framework for the healthcare system in Denmark.

semaglutide

Cited by Canadian Agency for Drugs and Technologies in Health on 17 Jun 2019

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.